Advanced search    

Search: authors:"Anupkumar R. Anvikar"

10 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Improved access to early diagnosis and complete treatment of malaria in Odisha, India

Valecha. Formal analysis: Sreya Pradhan, Ambarish Dutta. Funding acquisition: Anupkumar R. Anvikar. Project administration: Sreya Pradhan, Madan Mohan Pradhan, Naman K. Shah. Supervision: Pyare Lal Joshi ... , Anupkumar R. Anvikar. Writing ? original draft: Sreya Pradhan. Writing ? review & editing: Khageshwar Pradhan, S. K. Sharma, Jaya Banerji, Stephan Duparc, Kamini Mendis, Shiva Murugasampillay, Neena

Malaria diagnosis by PCR revealed differential distribution of mono and mixed species infections by Plasmodium falciparum and P. vivax in India

, Aparup Das. Formal analysis: Nisha Siwal, Upasana Shyamsunder Singh, Aparup Das. Funding acquisition: Anupkumar R. Anvikar, Aparup Das. Investigation: Veena Pande, Aparup Das. Methodology: Nisha Siwal

Epidemiology of Plasmodium vivax Malaria in India

Medicines for Malaria Venture. The help provided by Sanjiv Gupta in preparing the maps is also acknowledged. Authors’ addresses: Anupkumar R. Anvikar, Naman Shah, and Neena Valecha, National Institute of

Pharmacovigilance Practices for Better Healthcare Delivery: Knowledge and Attitude Study in the National Malaria Control Programme of India

the questionnaire, collected and analyzed the data, and drafted the paper. Neena Valecha contributed to the study design, data collection, and paper preparation. Anupkumar R. Anvikar contributed to the

Pharmacovigilance Practices for Better Healthcare Delivery: Knowledge and Attitude Study in the National Malaria Control Programme of India

the questionnaire, collected and analyzed the data, and drafted the paper. Neena Valecha contributed to the study design, data collection, and paper preparation. Anupkumar R. Anvikar contributed to the

Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India

Background Anti-malarial drug resistance in Plasmodium falciparum in India has historically travelled from northeast India along the Myanmar border. The treatment policy for P. falciparum in the region was, therefore, changed from chloroquine to artesunate (AS) plus sulphadoxine-pyrimethamine (SP) in selected areas in 2005 and in 2008 it became the first-line treatment...

A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India

Background Artesunate + sulphadoxine-pyrimethamine (AS + SP) is recommended throughout India as the first-line treatment for uncomplicated falciparum malaria. Due to the presence of several eco-epidemiological zones of malaria and variable drug pressure, it is necessary to evaluate the efficacy of this combination in different regions of India. The objective of this study was to...

Genetic variation in histidine rich proteins among Indian Plasmodium falciparum population: possible cause of variable sensitivity of malaria rapid diagnostic tests

Background Rapid diagnostic tests (RDTs) have revolutionized the diagnosis of malaria. Among the various factors affecting RDTs sensitivity is genetic variation of the antigen used. The genetic variation in PfHRP2 and PfHRP3 proteins was studied among the Indian Plasmodium falciparum isolates. Methods One hundred and forty isolates of P. falciparum were collected from six...

Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India

Background Artemisinin-based combination therapy (ACT) has been recommended for the treatment of falciparum malaria by the World Health Organization. Though India has already switched to ACT for treating falciparum malaria, there is need to have multiple options of alternative forms of ACT. A randomized trial was conducted to assess the safety and efficacy of the fixed dose...

Prescription practices and availability of artemisinin monotherapy in India: where do we stand?

Background The World Health Organization has urged all member states to deploy artemisinin-based combination therapy and progressively withdraw oral artemisinin monotherapies from the market due to their high recrudescence rates and to reduce the risk of drug resistance. Prescription practices by physicians and the availability of oral artemisinin monotherapies with pharmacists...